Previous studies in ER+ breast cancer tissues had already suggested that alteration of the Scrib complex proteins Lgl2, Scrib, and Dlg5 could boost Tamoxifen resistance (Liu et al., 2019a; Saito et al., 2019). The gene discussed is SCRIB; the disease is breast cancer.